News roundup [abridged versions appear in the paper journal]

Firm involved in drug trial fiasco files for bankruptcy

BMJ 2006; 333 doi: 10.1136/bmj.333.7559.114-a (Published 13 July 2006)
Cite this as: BMJ 2006;333:114.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Owen Dyer
  1. London

    TeGenero, the German biotechnology firm whose experimental drug TGN1412 caused multiple organ failure in six men during a clinical trial in England, has filed for bankruptcy.

    “The unforeseeable adverse reactions caused by TGN1412 in the TGN1412-HV phase I trial have made it impossible to attract the investment necessary for the company to continue operations,” the company said in a statement. “In view of the fact that there appears [to be] no reasonable prospect that the company can continue its business, TeGenero's management had no alternative but to commence insolvency proceedings.”

    The Bavarian company, founded in 2000 by scientists from Würzburg University, will be administered by an official receiver as …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular